Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.
Frequently asked questions
What sector does Lytix Biopharma AS (LYTIX) operate in?
Lytix Biopharma AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Lytix Biopharma AS (LYTIX) current stock price?
As of the latest data, Lytix Biopharma AS stock price is NOK 8.00, with a previous close of NOK 8.04. Lytix Biopharma AS lost -NOK 0.04 in the last trading session, representing a -0.5% loss.
What is Lytix Biopharma AS (LYTIX) current market capitalization?
Lytix Biopharma AS market cap is approximately 615.20 million.
What is Lytix Biopharma AS (LYTIX) Earnings Per Share (EPS)?
The trailing EPS is -NOK 1.02, and the forward EPS is -NOK 1.37.
Does Lytix Biopharma AS (LYTIX) pay dividends?
No. Lytix Biopharma AS does not pay a dividend.
When is Lytix Biopharma AS (LYTIX) next earnings report?
Lytix Biopharma AS is expected to release its next earnings report on June 30, 2026.
What is Lytix Biopharma AS (LYTIX) beta (volatility) score?
Lytix Biopharma AS has a beta of -0.494, indicating lower volatility than the overall market.
